World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
62
Citations
19331
World Ranking
2828
National Ranking
250

Overview

Chloe Orkin is affiliated with Queen Mary University of London in the United Kingdom. Their research primarily spans the fields of medicine, immunology, and microbiology, with a significant focus on infectious diseases and virology.

The scientist's main fields of study include:

  • Medicine
  • Immunology and Microbiology

Within these areas, specific subfields of study covered are:

  • Infectious Diseases
  • Virology
  • Epidemiology
  • Molecular Biology
  • Emergency Medicine

The topics central to their work concentrate on HIV/AIDS and related infectious conditions, involving:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • Poxvirus research and outbreaks
  • HIV-related health complications and treatments
  • Bacillus and Francisella bacterial research
  • Herpesvirus Infections and Treatments

Chloe Orkin has contributed to numerous publications, including these recent papers:

  • "Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022" (2022) in New England Journal of Medicine
  • "Monkeypox" (2022) in The Lancet
  • "Mpox in people with advanced HIV infection: a global case series" (2023) in The Lancet
  • "Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection" (2020) in New England Journal of Medicine
  • "Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study" (2021) in The Lancet HIV

The frequent co-authors collaborating with Chloe Orkin include:

  • Vanessa Apea
  • Sara Paparini
  • Melanie Smuk
  • John Thornhill
  • Laura Waters

Publication venues where the scientist has regularly contributed include:

  • The Lancet HIV
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HIV Medicine
  • Open Forum Infectious Diseases
  • SSRN Electronic Journal

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

    Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  • Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

    Margaret T. May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    Francois Raffi;Anita Rachlis;Hans-Jürgen Stellbrink;W David Hardy

  • Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

    Davide Corti;Johannes P. M. Langedijk;Andreas Hinz;Michael S. Seaman

  • Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

    Margaret T May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

    Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  • Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

    Chloe Orkin;Keikawus Arasteh;Miguel Górgolas Hernández-Mora;Vadim Pokrovsky

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

    Anthony Mills;Jose R. Arribas;Jaime Andrade-Villanueva;Giovanni DiPerri

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Brief Communication: Rituximab in HIV-associated Multicentric Castleman Disease

    Mark Bower;Tom Powles;Sarah Williams;Tom Newsom Davis

  • British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011

    D Asboe;C Aitken;M Boffito;C Booth

  • Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Elchonon M. Berkowitz;Graeme Moyle;Hans-Jürgen Stellbrink;Dirk Schürmann

  • Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial†

    C Orkin;E DeJesus;H Khanlou;A Stoehr

  • Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

    Jean Michel Molina;Chloe Orkin;David M. Iser;Francisco Xavier Zamora

  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

    Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  • Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

    Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  • Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

    Jurgen Rockstroh;Karine Lacombe;Rolando M Viani;Chloe Orkin

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

    Duncan Churchill;Laura Waters;Nadia Ahmed;Brian Angus

  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes

    Zobair M. Younossi;Maria Stepanova;Mark Sulkowski;Susanna Naggie

Frequent Co-Authors

Clifford Leen
Clifford Leen Western General Hospital
Martin Fisher
Martin Fisher University of Sussex
Caroline Sabin
Caroline Sabin University College London
Frank A. Post
Frank A. Post King's College London
David Dunn
David Dunn University College London
Richard Gilson
Richard Gilson University College London
Philippa Easterbrook
Philippa Easterbrook King's College London
Andrew N. Phillips
Andrew N. Phillips University College London
Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Mark Nelson
Mark Nelson University of Vermont

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring microbiology in the USA opens doors to diverse online degrees and career opportunities beyond traditional lab roles. For individuals facing unique challenges, there are accessible options to pursue education, such as degrees felons can get, which include many health-related programs offering a fresh start.

One promising route is becoming a functional medicine nurse practitioner, blending microbiology knowledge with patient care. Those interested can explore functional medicine nurse practitioner programs online, which provide specialized training in holistic health approaches.

For careers focused on healthcare data rather than direct patient interaction, medical coding presents a viable option. Understanding the cpc medical coding salary and career paths can help students leverage microbiology background into coding and billing roles crucial for health systems.

Similarly, health information management offers leadership potential combining science and administration. The health information management degree salary reflects strong demand, making it an attractive pathway for microbiology graduates interested in managing patient data and health records.

Best Scientists Citing Chloe Orkin

Trending Scientists